Calidi Biotherapeutics to Showcase Advancing Clinical Pipelines at RedChip Virtual Investor Conference

The biotech company will present its novel RedTail virotherapy platform and lead candidate CLD-401 at the April 16 event.

Apr. 16, 2026 at 2:06am

Got story updates? Submit your updates here. ›

A vibrant, neon-outlined illustration of a cancer cell or tumor structure, glowing with energy against a dark background, conceptually representing Calidi's targeted genetic medicine technology.Calidi's RedTail virotherapy platform aims to selectively target and remodel the tumor microenvironment, delivering potent genetic payloads to fight cancer.San Diego Today

Calidi Biotherapeutics, a biotechnology company pioneering targeted genetic medicines, announced it will participate in RedChip's upcoming virtual investor conference 'Biotech Resurgence: Platforms and Pipelines of Today's Innovators' on April 16, 2026. The full-day event will spotlight publicly traded companies advancing innovation across biotechnology, therapeutics, medical devices, diagnostics, and digital health. Calidi will discuss the progress of its RedTail virotherapy platform, including the lead candidate CLD-401 which is expected to file an IND by the end of 2026.

Why it matters

Calidi's RedTail platform is designed to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly at the tumor site. The company's participation in this investor conference highlights its advancements in developing next-generation healthcare solutions and expanding the functionality of the RedTail platform, which could have significant implications for cancer treatment.

The details

The RedTail platform features an engineered enveloped oncolytic virus intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. CLD-401, the lead candidate from the RedTail platform, is engineered to express high levels of IL-15 superagonist, a known T and NK-cell activator, in the tumor microenvironment. Calidi is also expanding the RedTail platform to enable in situ expression of T-cell engagers in solid tumors, including in combination with T-cell activating payloads such as IL15 SA.

  • Calidi expects to file an IND for CLD-401 by the end of 2026.
  • The RedChip virtual investor conference will take place on April 16, 2026.

The players

Calidi Biotherapeutics

A biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease.

RedChip Companies

An investment research and corporate communications firm that is hosting the virtual investor conference where Calidi will present.

Eric Poma, PhD

Chief Executive Officer of Calidi Biotherapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“I look forward to discussing the advances we've made with the RedTail platform and the path to IND filing expected this year for CLD-401”

— Eric Poma, PhD, Chief Executive Officer

What’s next

Calidi plans to file an IND for its lead candidate CLD-401 by the end of 2026.

The takeaway

Calidi's participation in this investor conference showcases its progress in developing innovative virotherapy platforms that could revolutionize cancer treatment by selectively targeting tumors and delivering potent genetic payloads. The company's advancements with the RedTail platform, including the expected IND filing for CLD-401, position Calidi as a leader in the field of targeted genetic medicines.